Lee, A;
Waterhouse, J;
Linch, M;
(2020)
Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update.
EMJ Oncology
, 8
(3)
10.33590/emj/20-00044.
Preview |
Text
Lee_Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma- A 2020 Update_VoR.pdf - Published Version Download (626kB) | Preview |
Abstract
Advanced urothelial cancer (aUC) is invariably lethal and standard of care, platinum-based chemotherapy has changed little over the past 25 years. However, the past 5 years have been transformational with the advent of immunotherapies and targeted therapies. In this review, the authors focus on the therapies that are showing the greatest promise and have changed, or will imminently impact, the treatment landscape of aUC. Checkpoint inhibition is showing deep and durable responses in some patients and trial activity is concentrated on identifying the most suitable position within the treatment paradigm along with the most appropriate patients and therapeutic combinations. Novel targeted therapies in aUC are gaining renewed interest with nectin-4 antibody drug conjugates and fibroblast growth factor receptor inhibitors, both receiving recent regulatory approvals. Bispecific antibodies, capable of binding to two targets at the same time, are also showing promise. This review discusses the preclinical data, the relevant past, and present clinical trials along with regulatory status to provide a concise overview of the current and impending treatment options for aUC.
| Type: | Article |
|---|---|
| Title: | Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.33590/emj/20-00044 |
| Publisher version: | https://doi.org/10.33590/emj/20-00044 |
| Language: | English |
| Additional information: | © 2020 European Medical Group LTD. Published under a Creative Commons license (https://creativecommons.org/licenses/by-nc/4.0/). |
| Keywords: | Antibody-drug conjugates (ADC), bispecific antibodies, bladder cancer, enfortumab vedotin (EV), fibroblast growth factor receptor (FGFR), immunotherapy, nectin-4, targeted therapies, urothelial cancer |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10110435 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
